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Objective: The aim of this study was to investigate pharmacological treatment adherence of
patients with juvenile idiopathic arthritis, attended in an outpatient pharmacy at a tertiary
hospital in northeastern Brazil.
Methods: The analysis of adherence was performed along with caregivers, through a struc-
tured questionnaire based on Morisky, Green and Levine, which enabled the categorization
of  adherence in “highest”, “moderate” or “low” grades, and through evaluating medication
dispensing registers, which classiﬁed the act of getting medications at the pharmacy as
“regular” or “irregular”. Drug Related Problems (DRP) were identiﬁed through the narrative
of  caregivers and classiﬁed according to the Second Granada Consensus. Then, a pharma-
ceutical orientation chart with information about the therapeutic regimen was applied, in
order to function as a guide for issues that inﬂuenced adherence.
Results: A total of 43 patients was included, with a mean age of 11.12 years, and 65.1% (n = 28)
were  female. Applying the questionnaire, it was found “highest” adherence in 46.5% (n = 20)
patients, “moderate” adherence in 48.8% (n = 21), and “low” adherence in 4.7% (n = 2). Through
an  analysis of the medication dispensing registers, a lower level of adherence was observed:
only  25.6% (n = 11) of the participants received “regularly” the medications. Twenty-six DRP
was  identiﬁed, and 84.6% (n = 22) were classiﬁed as real. There were no signiﬁcant associa-
tions between socio-demographic variables and adherence, although some caregivers have
reported difﬁculty in accessing the medicines and in understanding the treatment.
Conclusion: Our ﬁndings showed problems in the adherence process related to inattention,
forgetfulness and irregularity in getting medicines, reinforcing the need for the developmentof  strategies to facilitate a better understanding of treatment and to ensure adherence.Please cite this article in press as: Adriano LS, et al. Medication adherence in patients with juvenile idiopathic arthritis. Rev Bras Reumatol.
2016. http://dx.doi.org/10.1016/j.rbre.2016.05.004
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Adesão  ao  tratamento  farmacológico  em  pacientes  com  artrite  idiopática
juvenil  por  meio  de  questionários
Palavras-chave:
Adesão ao tratamento
farmacológico
Artrite juvenil idiopática
Atenc¸ão farmacêutica
r  e  s  u  m  o
Objetivo: Investigar a adesão ao tratamento farmacológico de pacientes com artrite
idiopática juvenil, atendidos na farmácia ambulatorial de hospital terciário do Nordeste
do  Brasil.
Métodos: A análise da adesão foi feita junto aos cuidadores, por meio de questionário estru-
turado com base no teste de Morisky, Green e Levine, que viabilizou a categorizac¸ão da
adesão em “máxima”, “moderada” ou “baixa”, e da avaliac¸ão dos registros de dispensac¸ão
dos  medicamentos, que classiﬁcou a retirada de medicamentos na farmácia como “regular”
ou  “irregular”. Os problemas relacionados com medicamentos (PRM) foram identiﬁcados por
meio  da narrativa dos cuidadores e classiﬁcados conforme o Segundo Consenso de Granada.
Em seguida, aplicou-se uma tabela de orientac¸ão farmacêutica, que contém informac¸ões
sobre o esquema terapêutico, de forma a esclarecer questões que inﬂuenciavam a adesão.
Resultados: Participaram 43 pacientes, com média de 11,12 anos, 65,1%, (n = 28) do sexo
feminino. Por meio do questionário, veriﬁcou-se adesão “máxima” em 46,5% (n = 20)
dos  pacientes, “moderada” em 48,8% (n = 21) e “baixa” em 4,7% (n = 2). Pelo registro de
dispensac¸ão,  observou-se um nível de adesão menor: apenas 25,6% (n = 11) dos participantes
receberam os medicamentos “regularmente”. Identiﬁcaram-se 26 PRM, 84,6% (n = 22) clas-
siﬁcados como “reais”. Não foram observadas associac¸ões signiﬁcativas entre as variáveis
sociodemográﬁcas e a adesão, embora alguns cuidadores tenham relatado diﬁculdade de
acesso ao medicamento e de compreensão do tratamento.
Conclusão: Nossos achados demonstraram falhas no processo de adesão, relacionadas ao
descuido, esquecimento e à irregularidade para receber os medicamentos, o que reforc¸a a
necessidade de estratégias para facilitar a compreensão do tratamento e garantir a adesão.
©  2016 Publicado por Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma
c¸a  Clicen
Introduction
Juvenile idiopathic arthritis (JIA) refers to a clinically heteroge-
neous group of patients with arthritis of unknown cause, with
more  than six weeks duration that starts up to 16 years old.1
The treatment of arthritis includes education of the patient
and his family, drug therapy, physiotherapy, psychosocial sup-
port, occupational therapy and surgical approaches. In drug
therapies, generally anti-inﬂammatory non-steroidal drugs,
corticosteroids, synthetic and biological disease-modifying
antirheumatic drugs, and immunosuppressants are used,2
in order to control pain and to achieve clinical inactivity or
remission.3
However, as the complete resolution of the disease is of
uncommon occurrence, most children and adolescents need
to use multiple medications for a long period of time, espe-
cially in polyarticular forms of arthritis.4 This aspect, along
with other factors, contributes to a poor adherence to treat-
ment of children and adolescents with chronic rheumatic
diseases.5
The World Health Organization considers that inadequate
adherence to treatment of chronic diseases is a worldwide
problem of great magnitude and deﬁnes that adherence toPlease cite this article in press as: Adriano LS, et al. Medication adheren
2016. http://dx.doi.org/10.1016/j.rbre.2016.05.004
treatment comprises a phenomenon subject to the inﬂuence
of multiple factors that directly affect the patient and deter-
mine the behavior with respect to the recommendations for
the treatment of disease and that, moreover, they are relatedC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
to socio-demographic conditions, the disease, the treatment,
the relationship of health professionals with the patient and
also to the patient him/herself.6
Crespo et al. suggested that physicians and pharma-
cists who follow the patient with arthritis should perform
integrated actions in an effort to identify the emergence
of problems related to prescription drugs, including non-
adherence to treatment and, from this point, carry out
interventions to reduce and prevent these problems.7
In this sense, the present study aimed to analyze the adher-
ence to pharmacological treatment of patients with Juvenile
Idiopathic Arthritis under outpatient monitoring in a pedi-
atric hospital in Northeastern Brazil, and identify drug-related
problems that can inﬂuence in this process.
Patients  and  methods
The study was conducted in an outpatient pharmacy of a
public hospital in northeastern Brazil, considered as a ref-
erence in tertiary care in pediatric area, where, in 2012, 130
patients with JIA were followed. Inclusion criteria were: child
or adolescent (17 years and 11 months), with a conﬁrmed
diagnosis of JIA through clinical and laboratory tests, consid-ce in patients with juvenile idiopathic arthritis. Rev Bras Reumatol.
ering: onset before age of 16, duration of symptoms less
than six weeks, with exclusion of the possibility of other
causes.1 The patient should be registered in the Specialized
Component for Pharmaceutical Assistance and the primary
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aregiver should attend the outpatient pharmacy of the hos-
ital during the study period in order to receive medicines.
e considered as primary caregiver that person who admin-
sters the medicine and/or monitors the treatment together
ith the pediatric patient, to obtain a sample by convenience.
xclusion criteria were: patients with caregivers showing any
imitations that prevented answering the questionnaire, or
hose companions were not the caregivers responsible by the
herapy.
The caregiver of each patient with JIA was asked to
nswer the questionnaire on adherence, composed of two
locks: the ﬁrst block approached sociodemographic data,
here variables related to the patient (gender and age) and
o the caregiver (education, origin, current working status
nd family income), as well as the degree of relationship
etween the caregiver and the patient were obtained; the
econd block dealt with the evaluation of adherence, with
n initial question that identiﬁed if the responsible for the
dministration of the drug was the caregiver or the child
imself, followed by four questions related to the adher-
nce according to Morisky, Green and Levine test (adapted),8
ith questions directed to the caregiver. Thus, each posi-
ive response was assigned a value of 1 point. A ﬁnal score
f zero indicated ‘high’ adherence, 1–2 indicated ‘moderate’
dherence, 3–4, ‘low’ adherence. An analysis of the num-
er of afﬁrmative answers to each question was performed,
n order to identify which parameter was more  related to
on-adherence.
After the questionnaire, the caregiver was asked to relate
ow the medicines were being used. The caregiver was free to
xpress their perceptions regarding the treatment in private
nd in a comfortable manner. From the reports, it was possible
o identify Drug Related Problems (DRP), which were classiﬁed,
ccording to the Second Consensus of Granada, in problems of
eed, effectiveness or safety.9 DRP rating was still considered
s ‘real’, when there was a manifestation, or ‘potential’, in the
ace of the possibility of ocurrence.10
In the face of the main difﬁculties of the caregiver regarding
reatment, a pharmaceutical orientation table was drawn up,
lled with information on the treatment regimen (dose, sched-
le, recommendations for intake with food, conservation),
ased on the medical prescription. At the time of dispensing
he drug, both the caregiver and the patient received the table
s well as the relevant guidelines.
Adherence to treatment was evaluated by analyzing
he drug dispensing registers of the outpatient pharmacy
hat provides the following medications for patients with
IA: chloroquine, azathioprine, leﬂunomide, cyclosporine,
ethotrexate, etanercept and adalimumab. During four
onths, the books and annotations of the outpatient phar-
acy  dispensing register were evaluated monthly for each
tudy participant, in order to verify the occurrence of delays
n obtaining the medicines by the caregiver. The analysis of
he drug dispensing registers was based on the method used
y Gomes et al., which ranked the obtaining of medicines in
he pharmacy as ‘regular’ or ‘irregular’.11Please cite this article in press as: Adriano LS, et al. Medication adheren
2016. http://dx.doi.org/10.1016/j.rbre.2016.05.004
An adjustment of the criteria used was carried out with
he purpose of its adaptation to the particular medica-
ions used for JIA, given that the dosage varies, namely, 6;x x x(x x):xxx–xxx 3
chloroquine, azathioprine, leﬂunomide and cyclosporine are
daily agents; methotrexate and etanercept, weekly agents;
and adalimumab, every other week agent. In the outpatient
pharmacy of the hospital, medications are received in sufﬁ-
cient quantity for one month. Thus, for patients users of daily
agents, it was considered as ‘irregular’ the delay of more  than
one day; for patients users of weekly agents, it was considered
as ‘irregular’ the delay of more  than eight days; and ﬁnally, for
patients users of every two weeks agents, it was considered as
‘irregular’ the delay of more  than two weeks.
Finally, we established a statistical relationship between
the level of adherence to treatment and socio-demographic
variables, using the Statistic Package for Social Sciences (SPSS)
version 16.0, and applying the chi-squared test with a signiﬁ-
cance criterion for p < 0.05.
The project was approved by the Hospital Research Ethics
Committee, within the regulations governing research on
human beings under registration number 097/2011. The
informed consent was signed by caregivers.
Results
Socio-demographic  proﬁle  of  patients  and  caregivers
A total of 43 patients participated in the study, of whom 65.1%
(n = 28) were female. The mean age of the patients was 11.12
years; 23.2% (n = 10) of patients were aged under 8 years, 51.2%
(n = 22) were aged between 8 and 14 years, and 25.6% (n = 11)
between 15 and 17 years.
Regarding the proﬁle of caregivers, none showed limitation
to answering the questionnaire. The mean age of the partici-
pants was 41.07 years, and 90.7% (n = 39) were female. Among
these caregivers, 76.8% (n = 33) were mothers of patients, 9.3%
(n = 4) were fathers and 13.9% (n = 6) had another relationship.
72.1% (n = 31) lived in the country and, with respect to working
status, 55.8% (n = 24) were employed, but generally had low
income: 44.2% (n = 19) earned less than the minimum wage,
51.2% (n = 22) earned one to two minimum wages  and 4.6%
(n = 2) earned more  than three times the minimum wage.  Only
32.6% (n = 14) of the caregivers had education above elemen-
tary school.
Evaluation  of  adherence  by  a  structured  questionnaire
Initially, in 81.4% (n = 35) of cases, the caregiver was identiﬁed
as the main responsible for the process of taking medicine
at home. However, caregivers reported that patients used to
be participatory, reminding the caregiver that it was time to
take the medicine, which shows the co-participation of chil-
dren/adolescents in the process of completing the treatment.
By analyzing the questionnaire, adherence was classiﬁed
as ‘high’ in 46.5% (n = 20), ‘moderate’ in 48.8% (n = 21) and ‘low’
in 4.7% (n = 2) of cases. We  noted that the question with the
highest number of positive responses (39.5%, n = 17) was on the
‘neglect with medication administration schedule,’ followed
by the question of ‘forgetting to administer the medicine’ce in patients with juvenile idiopathic arthritis. Rev Bras Reumatol.
(25.6%, n = 11) (Table 1).
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Table 1 – Proﬁle of afﬁrmative responses of caregivers
(n = 43) to the adapted questionnaire of Morisky, Green
and Levine.
Parameters evaluated Yes
n (%)
1. Forgetting to administer the medicine 11 (25.6)
2. Careless at times about taking the medicine 17 (39.5)
as well as the access to the medication through purchase,3. Discontinuing the medicine when feeling better 2 (4.7)
4. Discontinuing the medicine when feeling worse 4 (9.3)
Analysis  of  adherence  using  the  medication  dispensing
register
In the analysis of adherence using the medication dispensing
register, it was observed that during the four-month period
of the study, only 25.6% (n = 11) of participants received the
agents regularly in the outpatient pharmacy. 27.9% (n = 12) of
participants had an ‘irregular’ dispensation (a delay in one of
the study months), 30.2% (n = 13) had two ‘irregular’ dispensa-
tions and 16.3% (n = 7) had three ‘irregular’ dispensations.
Relationship  between  level  of  adherence  and
socio-demographic  variables
The relationship between adherence veriﬁed by the structured
questionnaire and socio-demographic variables of patients
and caregivers (Table 2) was evaluated. Concerning statisti-
cal analysis, patients with ‘low’ or ‘moderate’ adherence were
allocated in the same group.
The relationship of the variables with the adherence
assessed by an analysis of medications dispensing registers
was also established (Table 3). In this case, for statistical anal-
ysis, patients with at least one drug dispensation considered
as ‘irregular’ were placed in the same group.
In both cases, no statistically signiﬁcant relationship
between socio-demographic variables and adherence was
found, although caregivers not living in the state capital and
with low education level have reported greater difﬁculty in
accessing and understanding of the treatment, respectively.
Analysis  of  Drug  Related  Problems  and  implementation  of
the intervention  model
Based on medication dispensing registers, the proﬁle of
medicines’ use from Specialized Component of Pharmaceu-
tical Assistance for treatment of JIA was checked; it was
observed that 46.5% of the participating patients were taking
only methotrexate; 18.6% methotrexate + etanercept; 13.9%
methotrexate + leﬂunomide; 4.7% adalimumab; 4.7% azathio-
prine; 4.7% azathioprine + chloroquine; 2.3% cyclosporine;
2.3% leﬂunomide; and 2.3% methotrexate + adalimumab.
In the analysis of Drug Related Problems, based on the
reports of caregivers themselves about the treatment, it was
observed that, of the 43 respondents, 18 did some account in
which it was possible to identify one or more  DRP. As a whole,
26 DRP were identiﬁed and in most cases (38.5%, n = 10), thePlease cite this article in press as: Adriano LS, et al. Medication adheren
2016. http://dx.doi.org/10.1016/j.rbre.2016.05.004
problem was related to the lack of use of a necessary drug;
followed by a non-quantitative uncertainty with respect to
the drug (26.9%, n = 7); quantitative ineffectiveness of the drug 1 6;x  x x(x x):xxx–xxx
(19.2%, n = 5); problems arising from the use of an unneces-
sary drug (11.5%, n = 3) and non-quantitative ineffectiveness
of the drug (3.9%, n = 1). Of the total 26 DRP, 84.6% (n = 22) were
classiﬁed as ‘real’ and 15.4% (n = 4) as ‘potential’.
From the identiﬁcation of DRP, it was possible to direct
the implementation of the intervention model in order to
clarify the caregiver on the main issues that negatively inﬂu-
enced the treatment. The pharmaceutical orientation table
has been used as a strategy to facilitate the understanding
of the treatment, minimizing forgetfulness and, therefore,
improving adhesion.
Discussion
The results found showed that most patients had ‘moderate’
or ‘low’ adherence, which is related to compliance failure in at
least one of the asked items. It was noticed that the main ques-
tions associated with non-adherence were a carelessness with
the medication administration schedule and forgetfulness,
which justiﬁes the relevance of interventions, for example,
the table with the therapeutic regimen used, which organizes
the schedules of medication taken and prevents forgetfulness,
given that clinical improvement with JIA is related to an appro-
priate fulﬁllment of any suitable treatment.12
The socio-demographic proﬁle of the participating patients
was similar to that observed in other studies. We  found
a predominance of female patients, which was expected,
considering that JIA affects about three times more  women
than men.13
The highest frequency of patients aged 8–14 was also found
both in other national (such as the study by Santos et al.,
who reviewed the medical records of patients with JIA and fol-
lowed up at the Rheumatology Department of the Hospital das
Clínicas, Universidade Federal do Estado de Minas Gerais from
2003 to 2005, whose patients had a mean age of 13.7 years14)
and international studies, such as that by Feldman et al., con-
ducted in two hospitals in Vancouver, with 175 children with
JIA, where the mean age was 10.2 years.15
Regarding the proﬁle of caregivers, it was observed that this
task has been performed mainly by the patient’s mother – a
point already observed in another study of patients with JIA.16
The identiﬁcation of variables related to socio-
demographic proﬁle of caregivers was considered relevant for
the application of the questionnaire and also for implemen-
ting the intervention model, because this information allows
an initial inference of possible factors that can inﬂuence
adherence. The information on education level is relevant,
so that one can communicate the explanations adequately
for a clear understanding of the caregiver. The information of
the caregiver’s origin (most of caregivers in this study did not
live in the state capital) allows the identiﬁcation of a possible
difﬁculty of access to medicines that were dispensed by the
public health system only in the state capital. The low income
of many  caregivers may hinder the displacement of such
people from the municipalities where they live to the capital,ce in patients with juvenile idiopathic arthritis. Rev Bras Reumatol.
if necessary. The working status (it was reported that most
caregivers were employed) may be related to the difﬁculty to
take time off work to receive the medicine. However, the study
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Table 2 – Association between adherence to therapy assessed by the structured questionnaire and socio-demographic
variables of patients and caregivers (n = 43).
Variables Adherence to therapy, n (%) p-Valuea p < 0.05
Low/moderate High
Total 23 (53.5) 20 (46.5)
Patient’s gender
Female 16 (68.2) 12 (61.9) p = 0.666
Patient’s age (years)
<8 5 (22.7) 5 (23.8) p = 0.226
8–14 10 (40.9) 12 (61.9)
15–17 8 (36.4) 3 (14.3)
Caregiver’s age (years)
<37 5 (22.7) 5 (23.8) p = 0.967
37–47 12 (50.0) 10 (52.4)
>47 6 (27.3) 5 (23.8)
Caregiver’s gender
Female 20 (86.4) 19 (95.2) p = 0.607
Education
Elementary school 16 (68.2) 13 (66.7) p = 0.916
Origin
Capital 5 (22.7) 7 (33.3)
Countryside 18 (77.3) 13 (66.7) p = 0.438
Working
Yes 13 (54.5) 11 (57.1) p = 0.864
Income (MW)
< 1 11 (47.8) 8 (38.1) p = 0.432
d
t
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rMW, minimum wage.
a Signiﬁcant if p < 0.05, chi-squared test.
id not ﬁnd a statistically signiﬁcant relationship between
hese variables and adherence, possibly because the proﬁle of
he population served by the hospital is very homogeneous,
ot allowing the observation of differences between more  or
ess adherent groups.
Considering the mean age of patients participating in the
tudy, one can see that even in adolescence, the caregiver
articipates with the patient in the drug-taking process, as
ecommended in the literature, which highlights the impor-
ance of children to participate with their families in making
ecisions about their own treatment, in a manner appropriate
o their stage of development and to the nature of the health
roblem at hand.17
Regarding the assessment of the drug dispensing register,
his method is considered as suitable for detecting patients
t risk of not effectively taking the medication correctly or
ven of abandoning treatment.18 In the present study, through
he analysis of drug dispensing registers, it was possible to
how a lower level of adhesion than that observed with the
nalysis of the questionnaires. However, we cannot state in
ll cases that the irregularity in obtaining the medication in
he outpatient pharmacy is associated with non-adherence,
ecause in some situations the caregiver, living mainly in the
nterior, chose to buy the medicines (if they were availablePlease cite this article in press as: Adriano LS, et al. Medication adheren
2016. http://dx.doi.org/10.1016/j.rbre.2016.05.004
or sale directly to the consumer, such as cyclosporine and
zathioprine) or used drug leftovers from a change in dosing
egimen.As for the relationship between socio-demographic vari-
ables and adherence, and in a similar way with our ﬁndings,
the study by Feldman et al. found no association between
socioeconomic status and adherence to treatment in patients
with JIA. This same study found higher therapeutic compli-
ance reported by caregivers, who considered the high beneﬁt
of drug treatment in patients with JIA, that is, who understood
the usefulness of treatment, as well as among patients with
less severe disease, observed by counting functional joints.12
However, these parameters were not assessed in our study.
The results related to DRP reveal a more  frequent occur-
rence of necessity problems where the patient does not use a
drug that he/she needs, followed by security problems, where
the patient shows a non-quantitative uncertainty with the use
of the medication, which may be, for instance, an adverse
reaction. The risk of adverse events is a common problem
in patients with chronic rheumatic conditions with direct
inﬂuence on adherence, together with the high number of
medications and the duration and complexity of treatment.18
The study of Silva et al. reports that the implementation of
pharmaceutical interventions, from the identiﬁcation of the
DRP (seeking to provide clear and organized information in
relation to the therapeutic regimen) is an effective way to
optimize treatment. The pharmaceutical care in pediatricsce in patients with juvenile idiopathic arthritis. Rev Bras Reumatol.
has promoted the streamlining of regulations and the reduc-
tion of medication errors and of adverse events, as well as an
increased adherence to treatment.17
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Table 3 – Association between adherence to therapy assessed with the medication dispensing register and
socio-demographic variables of patients and caregivers (n = 43).
Variables Dispensing register (%) p-Valuea p < 0.05
Irregular Regular
Total 32 (74.4) 11 (25.6)
Patient’s gender
Female 20 (62.5) 8 (72.7) p = 0.719
Patient’s age (years)
< 8 9 (28.1) 1 (9.1) p = 0.230
8–14 14 (43.8) 8 (72.7)
15–17 9 (28.1) 2 (18.2)
Caregiver’s age (years)
<37 9 (28.1) 1 (9.1) p = 0.560
37–47 18 (56.3) 4 (36.4)
>47 5 (15.6) 6 (54.5)
Caregiver’s gender
Female 30 (93.7) 9 (81.8) p = 0.267
Education
Elementary School 20 (62.5) 9 (81.8) p = 0.291
Origin
Capital 10 (31.3) 2 (18.2) p = 0.698
Countryside 22 (68.7) 9 (81.8)
Working
Yes 16 (50.0) 8 (72.7) p = 0.294
Income (MW)
<1 15 (46.9) 4 (36.4) p = 0.728
MW, minimum wage.
ra Signiﬁcant if p < 0.05, chi-squared test.
Our study has some methodological limitations, also
perceived in other studies assessing the adherence in pediatric
patients with JIA, as the work of Feldman et al. These authors
argue that the application of questionnaires may be biased
to the extent that caregivers can report that that to them is
socially correct, overestimating patient compliance.12 Evalua-
tion of the drug dispensing register, while providing relevant
information, has its limitations, given that some medications
could be bought in private pharmacies; and bearing in mind
that this situation was not always reported by caregivers, we
cannot state how often this actually happened; in addition,
the fact that the drug is received by the caregiver does not
make it possible to state that the patient will actually take
it. Direct methods of assessment of adherence methods, such
as the determination of serum levels of drugs, would allow
us to obtain more  accurate results. In this study it was not
possible to assess the impact of the intervention model. It is
suggested that further studies to evaluate the treatment in
patients with JIA take into account the realization of a pharma-
cotherapeutic follow-up program, which will identify different
variables that were not addressed in this study, but which are
of great importance for the adherence to the pharmacological
treatment.
Our ﬁndings allow us to identify and understand differentPlease cite this article in press as: Adriano LS, et al. Medication adheren
2016. http://dx.doi.org/10.1016/j.rbre.2016.05.004
aspects related to the current scenario of adherence to phar-
macological treatment for JIA in the study population, and
ﬂaws were observed in the adherence process, mainly relatedto negligence with the medication administration schedule,
forgetfulness and irregularity in receiving the drugs, which
reinforces the need for strategies that facilitate understanding
about the treatment and ensure adherence.
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